Russia agrees to produce coronavirus vaccine Sputnik V in India
Russia's sovereign wealth fund and Indian
pharmaceutical company Hetero have agreed to produce over 100 million doses per
year in India of the Sputnik V vaccine against COVID-19, according to a statement on the
Sputnik V Twitter account on Friday.
Hetero and the Russian Direct Investment Fund
(RDIF), which has been backing the vaccine and marketing it globally, plan to
start production of Sputnik V in India at the beginning of 2021, the statement
said.
Phase II-III trials are ongoing in India, the
statement said. Drugmaker Dr Reddy's Laboratories Ltd has said it expects
late-stage trials to be completed by as early as March 2021. Read More
Comments
Post a Comment